Celltrion (068270) -
Event summary combining transcript, slides, and related documents.
Latest events from Celltrion
- Biosimilar growth and merger integration set an ambitious 2024 outlook, despite profit pressure.068270
Q4 2023 - Portfolio expansion, Zymfentra and AI-enabled R&D anchor the growth roadmap.068270Investor presentation
- Record 2Q24 sales and expanding biosimilar and novel-drug growth plans.068270Investor presentation
- Zymfentra and pipeline growth pair with CDMO expansion and higher shareholder returns.068270Investor presentation
- A broad biosimilar base supports an ADC and multispecific antibody pipeline advancing toward 2028 INDs.068270Investor presentation
- Targets combine rapid product expansion, higher profitability and 40% average shareholder returns.068270Investor presentation
- 2025 targets combine KRW 5T revenue with sharply lower COGS and stronger operating profit.068270Investor presentation
- Young products fuel 1Q growth as FY25 sales are forecast to reach KRW 5tn.068270Investor presentation
- Young-product growth lifted 3Q25 profit as biosimilar launches and capacity expanded.068270Investor presentation
- Young biologics drove 2Q25 profit growth as five launches target a larger market.068270Investor presentation